Introduction: The lack of accepted homogeneous criteria for the definition of some demyelinating diseases makes diagnostic characterization difficult and limits data interpretation and therapeutic recommendations. Recurrent encephalomyelitis (ADE-R) along with borderline cases of neuromyelitis optica (NMO) is especially controversial.
Neuromielitis óptica (NMO); Mielitis recurrente; Esclerosis múltiple reproducibilidad de los resultados y las recomendaciones terapéuticas. Especialmente controvertidas son las formas de encefalomielitis recurrentes (EAD-RR) y otras formas infrecuentes de neuromielitis óptica (NMO).
Introduction
Idiopathic acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease. It primarily affects children and is usually preceded by viral infections or vaccines, with a latency between 2 and 30 days and a higher incidence in winter. [1] [2] [3] [4] Its causes do not include infections [5] [6] [7] or neoplasms. 8 The aetiopathogenic hypothesis explains it as an inadequate immune response against antigens of the central nervous system (CNS), released after damage by neurotropic agents or by molecular analogy. 3, 4 The neurological manifestations of ADEM are often polysymptomatic, 1, 9 cerebral and, less commonly, medullar. The most common signs of ADEM in children 4 are alterations in level of consciousness or behaviour, 10 fever, meningism and epileptic crises. [1] [2] [3] 11, 12 In adults it is rare and the most prevalent symptoms are motor, sensory, ataxia and alterations in speech or level of consciousness. 2, 4, 9, 13 ADEM is usually monophasic, 3 although 5.5%-25% of cases present recurrences. 10 These may occur in the same initial topography (ADEM-R) and, for some authors, in other locations (multiphasic ADEM).
1,2,4,10 Both of them, especially the multiphasic form, are the subject of much controversy since the differential diagnosis with MS 3,10,11 carries prognostic and therapeutic implications. 4 Radiologically, ADEM usually exhibits more extensive lesions in the cerebral white matter than those caused by MS. 1, 9 Gadolinium uptake is variable, 3 but a simultaneous uptake points more towards ADEM. 9 Gray matter lesions, mainly in the basal ganglia, may be bilateral and occur in up to 60% of cases, 9 while they are infrequent in the first demyelinating event in MS. The presence of ''Dawson's fingers'' in T1-weighted sequences should direct towards an alternative diagnosis to ADEM. 3, 11 Cerebrospinal fluid (CSF) may be normal or present lymphocytic pleocytosis and hyperproteinorrachia. 1 Oligoclonal bands (OCB) are often absent or disappear during follow-up, contrary to what has been described in MS. 1 Histopathologically, ADEM can be distinguished from MS by the existence in the former of perivenular demyelination ''bands'' with prominent inflammatory infiltrate at the expense of macrophages. Lesion margins are poorly defined. 14, 15 Typically, patients are treated with intravenous methylprednisolone (ivMTP) at high doses 3 during acute episodes.
Plasmapheresis 16, 17 and intravenous immunoglobulins 18 are therapeutic alternatives 9 in severe cases that are unresponsive to corticosteroids. The prognosis of monophasic ADEM is variable; 37%-81% of patients present a complete resolution of symptoms. 2, 11 Mortality (5%-25%) is associated with respiratory failure due to bulbar involvement. 4 There is little experience regarding the treatment of ADEM-R; some authors have proposed immunosuppressors, 12 cyclophosphamide 2,11,12 and mitoxantrone. 4, 12 For its part, neuromyelitis optica (NMO) or Devic's disease is characterised by recurrent episodes of optic neuritis and myelitis, which are usually disabling. 15, 19 Infrequently, NMO may present bulbar symptoms, such as hyperemesis and respiratory dysfunction, or even appear as a transverse myelitis. 20 The MRI scan of NMO usually reveals extensive medullar lesions of more than vertebral 3 segments 18, 20 and, in most cases, the cerebral white matter is normal. Determination of the anti-aquaporin 4 antibody in 2004 21 enabled differentiation between this entity and MS and the detection of intermediate or ''NMO spectrum'' forms whose evolution is still to be determined. 19, 20 However, false negatives can reach 30%-45% of the total, especially in cases treated with immunosuppressive drugs. 19 Therapeutic options during the acute phase include intravenous methylprednisolone (ivMTP) 20 and occasionally plasmapheresis 17 or intravenous immunoglobulins (ivIg). 18 As in ADEM-R, there are currently no randomised trials evaluating the treatment of recurrent NMO to prevent recurrences.
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Objective
The aim of this study is to describe the clinical and radiological characteristics of a 21-year-old female patient with recurrent rhombencephalomyelitis who was monitored for 9 years, as well as to discuss diagnostic options and therapeutic considerations.
Patient and methods
The patient was a 21-year-old female with no prior history of systemic or autoimmune disease, diagnosed with gastritis at the emergency department in February 2003, due to a 2-day history of vomiting, fever and mesogastric pain. Eight days later she reported progressive difficulty swallowing odynophagia, and uncontrollable vomiting. A thoracoabdominal CT scan and an urgent endoscopy were both normal.
Subsequently, the patient was again examined due to dyspnoea, pharyngeal foreign body sensation, phonatory difficulty and choking, with lancinating pain and painful dysesthesia throughout a broad band in the thoracolumbar region. She had no history of vaccination or infection prior to these symptoms. The general physical examination was normal. Upon exploration by a neurologist she presented limitation of left eye abduction and multidirectional nystagmus in all gaze positions, abolition of the gag reflex, significant dysarthria and breathing difficulty. Barre's manoeuvre was positive in the right upper limb and osteotendinous reflexes were hypoactive. She presented a band of hypoalgesia at the level of D4-L1, altered proprioceptive sensitivity in all four limbs, and dysmetria in the left upper limb. Visual acuity and fundus were normal.
A cranial MRI scan (Fig. 1A) showed hyperintense lesions in T2 sequences in two-thirds of the dorsal bulb, with compression of the fourth ventricle and left cerebellar peduncle. A spinal MRI scan (Fig. 1B) revealed a hyperintense band from C4 to L1 in T2-weighted sequences. The CSF presented pleocytosis (50/l) with monocyte predominance, sterility, proteins at 62 mg/dl and glucose at 84 mg/dl. The IgG index was normal and OCBs were not obtained. The microbiological study ruled out infectious aetiologies (Borrelia, Brucella, Mycoplasma, parvovirus, cytomegalovirus, herpes virus, varicella-zoster virus, Epstein-Barr virus, toxoplasmosis, enteroviruses, mycobacteria, acquired immunodeficiency virus, hepatitis C and HBV virus, Listeria, Gram, auramine). The serological study ruled out autoimmune or tumoural causes.
The initial diagnosis was autoimmune rhombencephalomyelitis. The patient was admitted to the intensive care unit with respiratory distress secondary to aspiration pneumonia. She was treated with broad-spectrum antibiotics and ivMTP for 5 days. Due to her poor response to corticosteroids, she was treated with 5 cycles of plasmapheresis followed by iv Ig at doses of 0.4 mg/kg/day for 5 days. At discharge, 1 month after admission, she presented paresis of the left sixth cranial nerve, multidirectional nystagmus and walked unaided, but was unsteady.
Subsequently, the patient presented 7 spontaneous relapses ( Table 1) . Of these 7 relapses, 4 consisted in mildmoderate myelitis with motor and/or sensory involvement, all at the dorsal level, from which she recovered after a few days. The first relapse coincided with removal of glucocorticoids. Treatment with azathioprine was started. The remaining relapses consisted of bilateral, paroxysmal pain in a half-band, associated with bilateral metameric hypoalgesia at the level of D5-D10. During the clinical course, visual evoked potentials were normal and serologies for HTLV-1 and anti-aquaporin 4, conducted during one of the relapses (May 2007), were negative. Regarding the MRI scan, the medullar lesion showed gadolinium uptake during various clinical relapses, whilst no other cranial or spinal injuries or signs of axonal damage were observed (Fig. 2) .
The patient was chronically treated with azathioprine at doses of 50 mg/12 h and, given the persistence of relapses, azathioprine was replaced by mycophenolate mofetil at doses of 1-1.5 g/day. At present, the patient has not suffered relapses for 3 years, she can walk and jump normally and exploration has only revealed the persistence of upwards vertical and bilateral horizontal nystagmus, without functional interference.
Discussion
This case suggests a form of recurrent rhombencephalomyelitis compatible with ADEM-R by clinical and radiological criteria, with a good clinical course and therapeutic response to immunosuppressors. At present, the patient is clinically asymptomatic after 7 relapses, despite having presented moderate disability during 3 of them. Notably, all relapses were in the same location as the initial event, although with different severity, and only the first relapse could be attributed to the gradual withdrawal of glucocorticoids. Images from the brain and medullar MRI scans were extensive, with medullar thickening similar to that described in exceptional cases of ADEM, 2, 10 and unusual for MS. The medullar images captured contrast on at least 2 occasions, coinciding with an exacerbation of symptoms. It is striking that after 7 recurrences, there were no observations of medullar necrosis or black holes in the brain MRI, suggesting the absence of axonal lesions, more typical in MS. The evolution of the case and the data presented excluded the diagnosis of MS. 22 The boundary with NMO is even more controversial. 23 From the clinical standpoint, our patient did not present the visual symptoms typical of NMO at any time during her evolution, and her evoked potentials were normal. Full recovery of the episodes without disability is rare in NMO. 15, 19, 23, 24 Although in our patient the medullar images resembled those described for NMO, 24 they did not show evidence of tissue necrosis, as is usual in NMO. 15, 24 Nevertheless, there have recently been reports of cases in which radiographic abnormalities improved or even disappeared between episodes. 20 The determination of IgG versus AQP4 was negative, although this determination was conducted under immunosuppressive treatment, so we cannot definitively rule out the possibility that our patient suffered an uncommon form of recurrent NMO according to the current criteria. 20, 24 The clinical evolution and negative result of microbiological and immunological tests conducted at the onset and during several of the episodes excluded other entities which could mimic these symptoms.
There is no clear consensus regarding treatment. During the initial outbreak, the patient was treated with ivMTP at high doses. Due to the severity of the outbreak and the incomplete response, she was subsequently treated with plasmapheresis and iv Ig, with marked clinical improvement. 16, 17 Treatment with azathioprine was established after the first relapse, following reports of good response to this drug. 12, 24, 25 The outbreaks persisted, so it was switched to mycophenolate mofetil, useful in other autoimmune diseases including NMO and MS. 25 This drug acts by inducing apoptosis of reactive T cells and decreasing humoral reactivity. 26 The patient has remained asymptomatic for two and a half years. 
Conclusions
Our study illustrates the observation that in certain cases of demyelinating diseases, diagnostic characterisation is not easy, despite the current criteria. We believe that our case presents clinical and radiological data matching both adult onset ADEM-R and an unusual form of NMO. The excellent medium-term prognosis with immunosuppressive therapy is more suggestive of a rare form of ADEM-R. Treatment with mycophenolate mofetil may be an alternative therapy for these patients.
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